Published in Semin Oncol on June 01, 2013
Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology (2013) 2.24
Androgen receptor as a driver of therapeutic resistance in advanced prostate cancer. Int J Biol Sci (2014) 1.07
A role for WDR5 in integrating threonine 11 phosphorylation to lysine 4 methylation on histone H3 during androgen signaling and in prostate cancer. Mol Cell (2014) 1.02
Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men. Theranostics (2014) 1.00
Nonsteroidal anti-inflammatory drugs and prostatic diseases. Biomed Res Int (2014) 0.91
The Multifaceted Roles of STAT3 Signaling in the Progression of Prostate Cancer. Cancers (Basel) (2014) 0.91
The Quantitative Criteria Based on the Fractal Dimensions, Entropy, and Lacunarity for the Spatial Distribution of Cancer Cell Nuclei Enable Identification of Low or High Aggressive Prostate Carcinomas. Front Physiol (2016) 0.86
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer. Asian J Androl (2014) 0.86
Insights into Chemoresistance of Prostate Cancer. Int J Biol Sci (2015) 0.86
Beyond abiraterone: new hormonal therapies for metastatic castration-resistant prostate cancer. Cancer Biol Ther (2013) 0.85
Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation. Mol Cell Pharmacol (2015) 0.81
Sortilin regulates progranulin action in castration-resistant prostate cancer cells. Endocrinology (2015) 0.80
Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice. PLoS One (2014) 0.79
Downregulation of Critical Oncogenes by the Selective SK2 Inhibitor ABC294640 Hinders Prostate Cancer Progression. Mol Cancer Res (2015) 0.78
Extracellular vesicles in prostate cancer: new future clinical strategies? Biomed Res Int (2014) 0.78
Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy. Nat Rev Urol (2015) 0.77
The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy. Cancer Biol Ther (2014) 0.77
mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity. Endocr Relat Cancer (2015) 0.77
The context of prostate cancer genomics in personalized medicine. Oncol Lett (2017) 0.75
Crosstalk of the Androgen Receptor with Transcriptional Collaborators: Potential Therapeutic Targets for Castration-Resistant Prostate Cancer. Cancers (Basel) (2017) 0.75
Testis specific Y-like 5: gene expression, methylation and implications for drug sensitivity in prostate carcinoma. BMC Cancer (2017) 0.75
Extracellular Vesicle-Mediated Reversal of Paclitaxel Resistance in Prostate Cancer. Crit Rev Oncog (2015) 0.75
Somatic Mutation Analyses in Studies of the Clonal Evolution and Diagnostic Targets of Prostate Cancer. Curr Genomics (2017) 0.75
Influence of chronic inflammation on Bcl-2 and PCNA expression in prostate needle biopsy specimens. Oncol Lett (2017) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Integrative genomic profiling of human prostate cancer. Cancer Cell (2010) 23.61
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature (2005) 15.83
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol (2009) 9.29
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell (2011) 7.32
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol (2004) 6.95
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell (2003) 6.38
Identification of a cell of origin for human prostate cancer. Science (2010) 6.33
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res (2009) 6.15
Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature (2011) 6.10
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene (2007) 5.79
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell (2009) 5.74
A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature (2009) 5.65
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A (2010) 5.59
Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res (2001) 5.11
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol (2011) 4.57
Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell (2011) 4.43
Roles for Nkx3.1 in prostate development and cancer. Genes Dev (1999) 4.30
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell (2010) 4.16
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. Cancer Res (2007) 3.82
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One (2011) 3.59
Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell (2011) 3.53
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res (1999) 3.41
Bmi-1 is a crucial regulator of prostate stem cell self-renewal and malignant transformation. Cell Stem Cell (2010) 3.41
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Pten deletion leads to the expansion of a prostatic stem/progenitor cell subpopulation and tumor initiation. Proc Natl Acad Sci U S A (2006) 3.34
Induced chromosomal proximity and gene fusions in prostate cancer. Science (2009) 3.31
Nuclear MYC protein overexpression is an early alteration in human prostate carcinogenesis. Mod Pathol (2008) 3.18
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene (2008) 2.94
ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A (2009) 2.93
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell (2012) 2.84
TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res (2006) 2.82
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res (2012) 2.81
Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res (1997) 2.80
Response of glandular versus basal rat ventral prostatic epithelial cells to androgen withdrawal and replacement. Prostate (1987) 2.70
Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res (2008) 2.58
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J (2011) 2.55
Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab (2010) 2.53
ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res (2012) 2.51
Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. Cancer Res (2012) 2.45
Senescence comes of age. Nat Med (2005) 2.39
Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal. J Biol Chem (2012) 2.25
Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell (2011) 2.23
MYC regulation of a "poor-prognosis" metastatic cancer cell state. Proc Natl Acad Sci U S A (2010) 2.21
Detection of somatic copy number alterations in cancer using targeted exome capture sequencing. Neoplasia (2011) 2.21
Akt-mediated phosphorylation of Bmi1 modulates its oncogenic potential, E3 ligase activity, and DNA damage repair activity in mouse prostate cancer. J Clin Invest (2012) 2.03
Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem (1995) 2.02
AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression. Oncogene (2012) 1.98
Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol (1998) 1.97
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
Regulation of androgen receptor and histone deacetylase 1 by Mdm2-mediated ubiquitylation. Nucleic Acids Res (2005) 1.83
Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res (2006) 1.83
Regulation of androgen receptor transcriptional activity and specificity by RNF6-induced ubiquitination. Cancer Cell (2009) 1.77
Molecular characterization of TMPRSS2-ERG gene fusion in the NCI-H660 prostate cancer cell line: a new perspective for an old model. Neoplasia (2007) 1.75
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1. EMBO J (2011) 1.72
Treatment-dependent androgen receptor mutations in prostate cancer exploit multiple mechanisms to evade therapy. Cancer Res (2009) 1.71
Roles of the Polycomb group proteins in stem cells and cancer. Cell Death Dis (2011) 1.70
Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J Natl Cancer Inst (1999) 1.70
MYC overexpression induces prostatic intraepithelial neoplasia and loss of Nkx3.1 in mouse luminal epithelial cells. PLoS One (2010) 1.65
Testosterone and prostate cancer: revisiting old paradigms. Eur Urol (2009) 1.65
Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest (2012) 1.63
Unopposed c-MYC expression in benign prostatic epithelium causes a cancer phenotype. Prostate (2005) 1.57
Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol (2006) 1.56
Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation (2008) 1.55
Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res (2009) 1.54
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
Inactivation of androgen-induced regulator ARD1 inhibits androgen receptor acetylation and prostate tumorigenesis. Proc Natl Acad Sci U S A (2012) 1.52
Cooperation between Polycomb and androgen receptor during oncogenic transformation. Genome Res (2011) 1.47
Prostatic intraepithelial neoplasia in mice expressing an androgen receptor transgene in prostate epithelium. Proc Natl Acad Sci U S A (2001) 1.43
The phosphorylation of the androgen receptor by TFIIH directs the ubiquitin/proteasome process. EMBO J (2010) 1.39
FOXA1: master of steroid receptor function in cancer. EMBO J (2011) 1.36
ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer. PLoS One (2010) 1.35
CDK9 regulates AR promoter selectivity and cell growth through serine 81 phosphorylation. Mol Endocrinol (2010) 1.35
A transcriptional repressor co-regulatory network governing androgen response in prostate cancers. EMBO J (2012) 1.32
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Chapel Hill bisphenol A expert panel consensus statement: integration of mechanisms, effects in animals and potential to impact human health at current levels of exposure. Reprod Toxicol (2007) 4.04
Tailoring to RB: tumour suppressor status and therapeutic response. Nat Rev Cancer (2008) 3.16
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
AR, the cell cycle, and prostate cancer. Nucl Recept Signal (2008) 2.44
The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Invest (2006) 2.18
Hijacking the chromatin remodeling machinery: impact of SWI/SNF perturbations in cancer. Cancer Res (2009) 2.03
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle (2010) 1.96
An evaluation of evidence for the carcinogenic activity of bisphenol A. Reprod Toxicol (2007) 1.83
Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors. Clin Cancer Res (2012) 1.78
The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol Cancer Ther (2002) 1.63
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci U S A (2006) 1.52
Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68. Cancer Res (2009) 1.52
PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res (2014) 1.39
Retinoblastoma tumor suppressor: where cancer meets the cell cycle. Exp Biol Med (Maywood) (2006) 1.38
Compensation of BRG-1 function by Brm: insight into the role of the core SWI-SNF subunits in retinoblastoma tumor suppressor signaling. J Biol Chem (2001) 1.37
FOXA1: master of steroid receptor function in cancer. EMBO J (2011) 1.36
Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer. Endocr Relat Cancer (2011) 1.35
BAF57 governs androgen receptor action and androgen-dependent proliferation through SWI/SNF. Mol Cell Biol (2005) 1.32
Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem (2001) 1.32
Cyclin D1b is aberrantly regulated in response to therapeutic challenge and promotes resistance to estrogen antagonists. Cancer Res (2008) 1.30
Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity. Cancer Res (2008) 1.26
Differential requirement of SWI/SNF for androgen receptor activity. J Biol Chem (2003) 1.23
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells. Cancer Res (2007) 1.23
The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer. Cancer Res (2008) 1.21
Androgen receptor corepressors and prostate cancer. Endocr Relat Cancer (2006) 1.17
Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res (2009) 1.17
A central domain of cyclin D1 mediates nuclear receptor corepressor activity. Oncogene (2005) 1.12
Bisphenol A facilitates bypass of androgen ablation therapy in prostate cancer. Mol Cancer Ther (2006) 1.11
Specificity of cyclin D1 for androgen receptor regulation. Cancer Res (2003) 1.06
Functional specificities of Brm and Brg-1 Swi/Snf ATPases in the feedback regulation of hepatic bile acid biosynthesis. Mol Cell Biol (2009) 1.06
Identification of ASF/SF2 as a critical, allele-specific effector of the cyclin D1b oncogene. Cancer Res (2010) 1.04
Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res (2005) 1.03
2,3,7,8-Tetrachlorodibenzo-p-dioxin blocks androgen-dependent cell proliferation of LNCaP cells through modulation of pRB phosphorylation. Mol Pharmacol (2004) 1.01
Ex vivo culture of human prostate tissue and drug development. Nat Rev Urol (2013) 1.00
The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle (2007) 1.00
Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res (2006) 0.99
The epigenetic modifier ubiquitin-specific protease 22 (USP22) regulates embryonic stem cell differentiation via transcriptional repression of sex-determining region Y-box 2 (SOX2). J Biol Chem (2013) 0.98
Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect (2007) 0.95
Time to stratify? The retinoblastoma protein in castrate-resistant prostate cancer. Nat Rev Urol (2011) 0.94
Aberrant BAF57 signaling facilitates prometastatic phenotypes. Clin Cancer Res (2013) 0.94
The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol (2011) 0.93
Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function. J Biol Chem (2011) 0.92
Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes. J Clin Invest (2012) 0.92
AR function in promoting metastatic prostate cancer. Cancer Metastasis Rev (2014) 0.91
Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology (2010) 0.90
Targeting PARP-1 allosteric regulation offers therapeutic potential against cancer. Cancer Res (2013) 0.89
mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer (2012) 0.89
USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. Cancer Res (2013) 0.88
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia (2013) 0.88
Targeting pioneering factor and hormone receptor cooperative pathways to suppress tumor progression. Cancer Res (2012) 0.85
Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. Mol Endocrinol (2014) 0.84
Postprostatectomy radiation therapy: an evidence-based review. Future Oncol (2011) 0.83
Caveolin-1 overexpression enhances androgen-dependent growth and proliferation in the mouse prostate. Int J Biochem Cell Biol (2011) 0.80
Practical guide to the use of radium 223 dichloride. Can J Urol (2014) 0.79
IGF2 revs the steroidogenesis engine. Endocr Relat Cancer (2013) 0.78
2,2-bis(4-chlorophenyl)-1,1-dichloroethylene stimulates androgen independence in prostate cancer cells through combinatorial activation of mutant androgen receptor and mitogen-activated protein kinase pathways. Mol Cancer Res (2008) 0.78
AMPed up to treat prostate cancer: novel AMPK activators emerge for cancer therapy. EMBO Mol Med (2014) 0.75
The role of tumor suppressor dysregulation in prostate cancer progression. Curr Drug Targets (2013) 0.75
A tale of three PKCs: epsilon emerges as a driver of pre-neoplastic phenotypes. Cell Cycle (2011) 0.75
Middlegame theory, cancer style: a message from the editor-in-chief. Mol Cancer Res (2013) 0.75